APRI Stock Chart & Historical Trading Data $APRI Updated:

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
397
APRI Stock Chart & Historical Trading Data $APRI Updated: 02-18-2017
Last Trade: 2/17/2017
Last 3.21   
Open 2.90
Previous Close 3.21
Day High / Low 3.49 / 2.84
Year High / Low 15.40 / 1.10
Volume 2,420,027
Projected Volume 2420027 (355%)
# of Trades / Projected 5,048 / 5,048
Dividend / Yield - / 0.00%
Abnormal Activity NONE
Abnormal Volume NO
Gap NONE
Candle BULLISH
Volatility Today MEDIUM
Volatility Yesterday LOW
Price Relativity
From 40 Day High 111%
From 80 Day High 111%
From 150 Day High 73%
From 40 Day Low 270%
From 80 Day Low 282%
From 150 Day Low 282%
Pivot Analysis
Price Pivot $ 3.18
Day Resistance 1 $ 3.52
Day Support 1 $ 2.87
Day Resistance 2 $ 3.83
Day Support 2 $ 2.53
Consolidations
Short Term NO
Medium Term YES
Long Term YES
Volume Indicators
20 Day Avg Vol 682,451
Today / 20 Day Avg Vol ABOVE
150 Day Avg Vol 915,232
Today / 150 Day Avg Vol ABOVE
Abnormal Volume NO
William Volume Accumulation bullish
Volume Price Trend bullish
Momentum Indicators
10 Day Trend bullish
40 Day Trend bullish
100 Day Trend bearish
Stochastics bearish
RSI neutral
MACD bullish
Moving Average Indictors
15 Day Trend bullish
45 Day Trend bullish
100 Day Trend bearish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? NONE
Volatility Index Today MEDIUM
Volatility Index Yesterday LOW
10 Day Volatility INCREASING
20 Day Volatility DECREASING
40 Day Volatility DECREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Revolutionary AI Improves Immunology and Cancer Research Efficiency

Updated Category News Views 107

Transforming Research with AI Technology BD (Becton, Dickinson and Company) (NYSE: BDX) has recently launched an innovative tool that is set to transform the landscape of immunology and cancer research. The introduction of the BD® Research Cloud 7.0, featuring the BD Horizon™ Panel Maker, is redefining how scientists approach experimental design in these critical...

Continue Reading
Strategic Collaboration of IONETIX and AlfaRim Medical Unveiled

Updated Category News Views 347

Strategic Partnership Between IONETIX and AlfaRim Medical In a significant move within the medical isotope industry, IONETIX Corporation has announced a strategic partnership with AlfaRim Medical B.V. This collaboration sets the stage for accelerating the commercial production of Actinium-225, a crucial isotope used in targeted alpha therapies for various cancers. As...

Continue Reading
Endeavour Silver's Terronera Project Achieves Major Milestones

Updated Category News Views 62

Endeavour Silver's Terronera Project Update: Key Developments Endeavour Silver Corp. (NYSE: EXK; TSX: EDR) has unveiled a significant third-quarter construction progress report for its Terronera Project located in Mexico. The company takes pride in its remarkable strides toward achieving full operational readiness. Progress Overview The Terronera Project has progressed...

Continue Reading
Healthcare Sector Faces Major Cybersecurity Challenges Amid Breaches

Updated Category News Views 224

Significant Rise in Healthcare Data Breaches In the healthcare industry, data breaches hit a dramatic peak, leading to an alarming tally of over 276 million records compromised. This stunning figure represents a staggering 64.1% increase from prior years, illustrating profound vulnerabilities in the protection of sensitive patient information. As such, the harsh reality...

Continue Reading
Tempus AI Investors Prepare for Class Action Opportunity

Updated Category News Views 131

Understanding the Tempus AI Class Action Lawsuit Investors in Tempus AI, Inc. (NASDAQ: TEM) may find themselves in a position to lead a class action lawsuit following substantial financial losses. This legal opportunity arises from significant allegations against the company, which purports to be advancing precision medicine through artificial intelligence. Who Can...

Continue Reading